Abiraterone with dalpiciclib for salivary gland cancer
Part of Cancer, Mouth & dental clinical trials.
This trial tests a combination of two targeted drugs for advanced salivary gland cancer that has spread or cannot be removed with surgery. The drugs may block hormones and slow cancer growth, potentially helping people whose tumors have specific markers.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old
- You have advanced or recurrent salivary gland cancer that cannot be surgically removed and shows a certain marker (AR-positive, HER2-negative)
- Your tumor sample is available for testing
- You are generally in good health (able to care for yourself, with normal organ function)
- You have not had anti-androgen therapy or CDK4/6 inhibitors before
- You are willing to use effective contraception if applicable
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a personalized treatment approach for recurrent or metastatic salivary gland cancer. It uses special tests on your tumor to find the best targeted therapy for your specific cancer type.
This trial tests a new drug combination (MRG003 with or without putrelimab) for people with advanced salivary gland cancer that has EGFR protein. It aims to see if the treatment is safe and helps shrink tumors.
This Phase 2 trial studies whether adding dutasteride to standard anti-androgen therapy can shrink or slow an advanced salivary gland cancer. It is for cancers that test “androgen receptor (AR) positive,” meaning they may respond to medicines that block male-hormone signals.
This trial tests a combination of two oral medications (darxiciclib and abiraterone) for men with advanced prostate cancer that has spread and no longer responds to standard hormone therapy. It may help if you have already tried one newer hormone therapy and are looking for another option.
This trial tests a new drug, Rezvilutamide, combined with standard hormone therapy for people with a rare and aggressive type of salivary gland cancer that has a high risk of coming back. The treatment aims to reduce the chance of cancer returning after surgery.
This trial tests a combination of a targeted antibody-drug and focused radiation for people with advanced or recurrent salivary gland cancer that has spread. It aims to see if this treatment can help control the disease when standard treatments have stopped working.
Hear when a new Salivary Gland Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.